Patents by Inventor Fengzhi Li

Fengzhi Li has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190237699
    Abstract: The flexible display device provided in the present disclosure includes: an organic light emitting structure; an organic layer covering the organic light emitting structure and filled with an inorganic material.
    Type: Application
    Filed: April 5, 2019
    Publication date: August 1, 2019
    Applicant: Yungu (Gu'an) Technology Co., Ltd.
    Inventors: Kun HU, Jiawei LI, Wangfeng XI, Mengzhen LI, Fengzhi YU, Yucheng LIU, Xiaokang ZHOU, Hui PANG, Feng YU
  • Patent number: 10344037
    Abstract: Described herein, are FL118 core structure platform compounds, matter of compositions, formulation, methods and uses for treating cancer or other human diseases. Chemical modifications of the FL118 structure are employed alone or in combination with other anti-cancer agents to preclude or reverse refractory cancer phenotypes and for unique personalized cancer treatment (personalized medicine or as Obama called precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogs.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: July 9, 2019
    Assignee: Canget BioTek Pharma LLC
    Inventors: Fengzhi Li, Xiang Ling
  • Publication number: 20180170944
    Abstract: Described herein, are FL118 core structure platform compounds, matter of compositions, formulation, methods and uses for treating cancer or other human diseases. Chemical modifications of the FL118 structure are employed alone or in combination with other anti-cancer agents to preclude or reverse refractory cancer phenotypes and for unique personalized cancer treatment (personalized medicine or as Obama called precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogues.
    Type: Application
    Filed: March 24, 2015
    Publication date: June 21, 2018
    Applicant: Canget BioTekpharma, LLC
    Inventors: Fengzhi LI, Xiang LING
  • Patent number: 9422303
    Abstract: Provided are compositions, methods of making the compositions, and methods of using the compositions. The compositions can be provided as pharmaceutical preparations for use in disease treatment, such as cancer therapy. The compositions include novel pharmaceutical preparations which contain effective concentrations of a chemical compound. One compound used is 10H-1,3-Dioxolo[4,5-g]pyrano[3?,4?:6,7]indolizino[1,2-b]quinoline-8,11(7H,12H)-dione, 7-ethyl-7-hydroxy-, (S)-. The invention also provides methodologies for preparing pharmaceutical preparations for use in intravenous and oral pharmaceutical preparations that contain drug compounds that are difficult to dissolve in water.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: August 23, 2016
    Assignee: Health Research, Inc.
    Inventors: Fengzhi Li, Xiang Ling, Shousong Cao
  • Publication number: 20140066470
    Abstract: Provided are compositions, methods of making the compositions, and methods of using the compositions. The compositions can be provided as pharmaceutical preparations for use in disease treatment, such as cancer therapy. The compositions include novel pharmaceutical preparations which contain effective concentrations of a chemical compound. One compound used is 10H-1,3-Dioxolo[4,5-g]pyrano[3?,4?:6,7]indolizino[1,2-b]quinoline-8,11(7H,12H)-dione, 7-ethyl-7-hydroxy-, (S)-. The invention also provides methodologies for preparing pharmaceutical preparations for use in intravenous and oral pharmaceutical preparations that contain drug compounds that are difficult to dissolve in water.
    Type: Application
    Filed: October 31, 2011
    Publication date: March 6, 2014
    Applicant: HEALTH RESEARCH, INC.
    Inventors: Fengzhi Li, Xiang Ling, Shousong Cao
  • Patent number: 8043815
    Abstract: Provided are methods for determining whether an individual is a candidate to receive treatment with a DNA methylation inhibitor. The method can be performed a biological sample of cancerous tissue of the individual. Determining that PDEF expression is absent or low and survivin expression is present identifies the individual as a candidate to receive a treatment with a DNA methylation inhibitor. The method also includes communicating the result of identifying an individual as a candidate for receiving a DNA methylation inhibitor to a health care provider.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: October 25, 2011
    Assignee: Health Research, Inc.
    Inventors: Fengzhi Li, Ali Ghadersohi, Pasha Apontes
  • Patent number: 7968708
    Abstract: Disclosed are compounds having the formula: wherein Z1 is an alkylene moiety; Q is a carboxylic acid derivative; and R1 and R2 are the same or different and are selected from the group consisting of alkyl, aryl, alkylcarbonyl, arylcarbonyl, hydroxycarbonyl, and alkoxycarbonyl or R1 and R2, taken together with the nitrogen atom to which they are bound, form a ring. Also disclosed are compounds having the formula: wherein Z1 is an alkylene moiety; Q is a carboxylic acid derivative; and R13 is selected from the group consisting of alkyl and aryl. The compounds can be used to modulate cell proliferation and/or apoptosis, for example, in the treatment of cancers and other proliferative diseases, disorders, and conditions.
    Type: Grant
    Filed: December 6, 2007
    Date of Patent: June 28, 2011
    Assignees: The Research Foundation of State University of New York, Health Research Inc.
    Inventors: David G. Hangauer, Fengzhi Li, Taher Hegab, Xiang Ling
  • Patent number: 7569221
    Abstract: Provided are compositions and methods for identifying agents that can modulate expression of the human survivin gene. The compositions include eukaryotic cells that contain a human survivin promoter sequence operably linked to a reporter gene. The method comprises determining whether a test agent can modulate transcription from a human survivin promoter sequence by adding a test agent to eukaryotic containing a human survivin promoter sequence operably linked to a reporter gene, measuring expression of the reporter gene and comparing expression of the reporter gene from to a control, wherein an increase or decrease of expression of the reporter gene relative to the control is indicative that the test agent can modulate transcription from a human survivin promoter. The method also comprises the use of SPlucTg mice for preclinical drug identification, including testing of candidate drug toxicity and efficacy.
    Type: Grant
    Filed: November 12, 2007
    Date of Patent: August 4, 2009
    Assignee: Health Research, Inc.
    Inventor: Fengzhi Li
  • Publication number: 20090081674
    Abstract: Provided are methods for determining whether an individual is a candidate to receive treatment with a DNA methylation inhibitor. The method can be performed a biological sample of cancerous tissue of the individual. Determining that PDEF expression is absent or low and survivin expression is present identifies the individual as a candidate to receive a treatment with a DNA methylation inhibitor.
    Type: Application
    Filed: August 6, 2008
    Publication date: March 26, 2009
    Applicant: HEALTH RESEARCH INC.
    Inventors: Fengzhi Li, Ali Ghadersohi, Pasha Apontes
  • Publication number: 20080161556
    Abstract: Disclosed are compounds having the formula: wherein Z1 is an alkylene moiety; Q is a carboxylic acid derivative; and R1 and R2 are the same or different and are selected from the group consisting of alkyl, aryl, alkylcarbonyl, arylcarbonyl, hydroxycarbonyl, and alkoxycarbonyl or R1 and R2, taken together with the nitrogen atom to which they are bound, form a ring. Also disclosed are compounds having the formula: wherein Z1 is an alkylene moiety; Q is a carboxylic acid derivative; and R13 is selected from the group consisting of alkyl and aryl. The compounds can be used to modulate cell proliferation and/or apoptosis, for example, in the treatment of cancers and other proliferative diseases, disorders, and conditions.
    Type: Application
    Filed: December 6, 2007
    Publication date: July 3, 2008
    Inventors: David G. Hangauer, Fengzhi Li, Taher Hegab, Xiang Ling
  • Publication number: 20080153101
    Abstract: Provided are compositions and methods for identifying agents that can modulate expression of the human survivin gene. The compositions include eukaryotic cells that contain a human survivin promoter sequence operably linked to a reporter gene. The method comprises determining whether a test agent can modulate transcription from a human survivin promoter sequence by adding a test agent to eukaryotic containing a human survivin promoter sequence operably linked to a reporter gene, measuring expression of the reporter gene and comparing expression of the reporter gene from to a control, wherein an increase or decrease of expression of the reporter gene relative to the control is indicative that the test agent can modulate transcription from a human survivin promoter. The method also comprises the use of SPlucTg mice for preclinical drug identification, including testing of candidate drug toxicity and efficacy.
    Type: Application
    Filed: November 12, 2007
    Publication date: June 26, 2008
    Inventor: Fengzhi Li
  • Publication number: 20070248692
    Abstract: Combination therapies are provided for the treatment of proliferative disorders which use a pentafluorobenzenesulfonamide of formula I and an antineoplastic agent.
    Type: Application
    Filed: March 16, 2007
    Publication date: October 25, 2007
    Applicants: AMGEN INC., HEALTH RESEARCH, INC.
    Inventors: Fengzhi Li, Xiang Ling, Youcef Rustum, Susan Schwendner, Pieter Timmermans, Jacqueline Walling
  • Publication number: 20050250854
    Abstract: Combination therapies are provided for the treatment of proliferative disorders which use a pentafluorobenzenesulfonamide of formula I and an antineoplastic agent.
    Type: Application
    Filed: November 23, 2004
    Publication date: November 10, 2005
    Applicants: Amgen Inc., Health Research, Inc.
    Inventors: Fengzhi Li, Xiang Ling, Youcef Rustum, Susan Schwendner, Pieter Timmermans, Jacqueline Walling